JP2007503388A5 - - Google Patents

Download PDF

Info

Publication number
JP2007503388A5
JP2007503388A5 JP2006523903A JP2006523903A JP2007503388A5 JP 2007503388 A5 JP2007503388 A5 JP 2007503388A5 JP 2006523903 A JP2006523903 A JP 2006523903A JP 2006523903 A JP2006523903 A JP 2006523903A JP 2007503388 A5 JP2007503388 A5 JP 2007503388A5
Authority
JP
Japan
Prior art keywords
substituted
group
alkyl
hydrogen
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007503388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/025683 external-priority patent/WO2005021546A1/en
Publication of JP2007503388A publication Critical patent/JP2007503388A/ja
Publication of JP2007503388A5 publication Critical patent/JP2007503388A5/ja
Pending legal-status Critical Current

Links

JP2006523903A 2003-08-22 2004-08-09 マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 Pending JP2007503388A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49744303P 2003-08-22 2003-08-22
PCT/US2004/025683 WO2005021546A1 (en) 2003-08-22 2004-08-09 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases

Publications (2)

Publication Number Publication Date
JP2007503388A JP2007503388A (ja) 2007-02-22
JP2007503388A5 true JP2007503388A5 (enExample) 2007-09-27

Family

ID=34272569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523903A Pending JP2007503388A (ja) 2003-08-22 2004-08-09 マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用

Country Status (13)

Country Link
US (2) US20050124604A1 (enExample)
EP (1) EP1656376A1 (enExample)
JP (1) JP2007503388A (enExample)
CN (1) CN1839133A (enExample)
AR (1) AR045471A1 (enExample)
AU (1) AU2004268941A1 (enExample)
BR (1) BRPI0413695A (enExample)
CA (1) CA2531506A1 (enExample)
MX (1) MXJL06000006A (enExample)
PE (1) PE20051112A1 (enExample)
TW (1) TW200524928A (enExample)
UY (1) UY28483A1 (enExample)
WO (1) WO2005021546A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060229314A1 (en) * 2005-03-24 2006-10-12 Jagadish Sircar Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
EP2111399A2 (en) 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
WO2008137084A2 (en) 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
JP5916730B2 (ja) * 2010-09-06 2016-05-11 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ アミド化合物
US9133164B2 (en) * 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
CN103360388B (zh) * 2012-04-10 2017-11-14 江苏先声药业有限公司 5‑氨基‑1，4‑二氢‑1，8‑萘啶衍生物及其药物组合物和用途
WO2015095052A1 (en) 2013-12-17 2015-06-25 Controlled Chemicals, Inc. Isoindolin-1-ones as macrophage migration inhibitory factor (mif) inhibitors
US20230322804A1 (en) * 2016-07-13 2023-10-12 bioMérieux Reagents for reversibly protecting biological molecules
CA3048217A1 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES2905676T3 (es) 2017-05-22 2022-04-11 Amgen Inc Inhibidores de KRAS G12C y métodos para su uso
CN111051306B (zh) 2017-09-08 2023-01-03 美国安进公司 Kras g12c的抑制剂及其使用方法
CN107556309B (zh) * 2017-09-11 2020-12-01 浙江永宁药业股份有限公司 多取代四氢萘啶类化合物的药物用途及其制备方法
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
EP3790886B1 (en) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012204A (es) * 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
RS64641B1 (sr) 2018-06-27 2023-10-31 Bristol Myers Squibb Co Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija
US11866430B2 (en) * 2018-06-27 2024-01-09 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
CA3132895C (en) * 2019-03-08 2024-05-14 Transthera Sciences (Nanjing), Inc. Uses of phosphodiesterase inhibitors
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CN114144414B (zh) 2019-05-21 2025-11-07 美国安进公司 固态形式
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
WO2021133751A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
MX2022007130A (es) 2019-12-23 2022-07-11 Bristol Myers Squibb Co Derivados de piperazina sustituidos utiles como activadores de celulas t.
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
WO2022093817A1 (en) * 2020-10-26 2022-05-05 Yale University Macrophage migration inhibitory factor inhibitors, and methods of making and using same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) * 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US4299814A (en) * 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
US4284768A (en) * 1980-07-02 1981-08-18 American Home Products Corporation 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
PH25993A (en) * 1984-02-22 1992-01-13 Wellcome Found Cloning of DNA for protozoal antigens
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
AU592753B2 (en) 1984-05-24 1990-01-25 Ciba-Geigy Ag Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications
US4708937A (en) * 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8602626D0 (en) * 1986-02-04 1986-03-12 Ciba Geigy Ag Neurite-promoting factor
DE3789413T2 (de) * 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI82144C (fi) * 1989-03-22 1991-01-10 Wallac Oy Foerfarande foer samtidig bestaemning av flera ligander.
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
US5328990A (en) * 1991-04-26 1994-07-12 The United States Of America As Represented By The Department Of Health And Human Services Isolation of macrophage migration inhibition factor from ocular lens
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
ATE474597T1 (de) 1993-05-17 2010-08-15 Cytokine Pharmasciences Inc Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt
US5650295A (en) * 1995-06-02 1997-07-22 Human Genone Sciences, Inc. Macrophage migration inhibitory factor-3
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
CA2250067A1 (en) 1996-04-18 1997-10-23 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US5883224A (en) * 1996-04-19 1999-03-16 Cytokine Sciences, Inc. Characterization of transfer factors and methods of use
JPH1171351A (ja) 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6413939B1 (en) * 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
EP1036192B1 (en) 1997-12-05 2003-02-26 PHARMACIA & UPJOHN COMPANY Fluorescence-based high throughput screening assays for protein kinases and phosphatases
US6238874B1 (en) * 1998-07-28 2001-05-29 Biometric Imaging, Inc. Cell motility assay
US6214343B1 (en) * 1999-05-24 2001-04-10 Ophidian Pharmaceuticals, Inc. Prevention and treatment of necrotizing enterocolitis
JP2003512353A (ja) * 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
WO2001032606A1 (en) * 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
JP2004521892A (ja) * 2000-12-20 2004-07-22 メルク　エンド　カムパニー　インコーポレーテッド （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
JP4117462B2 (ja) * 2001-07-03 2008-07-16 株式会社大塚製薬工場 ナフチリジンおよびキノリン誘導体
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US20060106102A1 (en) * 2002-06-07 2006-05-18 Eric Morand Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif)
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Similar Documents

Publication Publication Date Title
JP2010510976A5 (enExample)
JP4669564B2 (ja) ２−イミノ−チアゾリジン−４−オン誘導体の製造のための新規な方法
JP2019520402A5 (enExample)
JP2006507355A5 (enExample)
JP2008510770A5 (enExample)
JP2005535586A5 (enExample)
JP2014518543A5 (enExample)
JP2005500266A5 (enExample)
ES2651765T3 (es) Imidazopiridazinas sustituidas
JP2018501285A5 (enExample)
JP2006516143A5 (enExample)
JP2009545611A5 (enExample)
JP2021535164A5 (enExample)
JP2009515872A5 (enExample)
JP2005526076A5 (enExample)
JP2009527501A5 (enExample)
JP2010504908A5 (enExample)
JP2009524691A5 (enExample)
JP2008523069A5 (enExample)
JP2002534519A5 (enExample)
RU2003133448A (ru) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс- хемокинового рецептора
JP2004535447A5 (enExample)
JP2012532112A5 (enExample)
JP2007516180A5 (enExample)
JP2013526494A5 (enExample)